Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Acta Neurol Scand. 2009 Apr;119(4):233-8. doi: 10.1111/j.1600-0404.2008.01119.x. Epub 2008 Nov 24.

The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy.

Author information

  • 1Department of Epileptology, University of Bonn, Germany. j.wellmer@gmx.de

Abstract

OBJECTIVE:

To investigate the impact of zonisamide (ZNS) on body weight in patients with epilepsy.

METHODS:

A retrospective chart analysis of weight changes after initiation of ZNS (103 patients; 54 female; age 17-68 years). For 31 patients follow-up data after ZNS-withdrawal were available. Patients were categorized according to body-mass-index (BMI) <20, 20-25, and >25 kg/m(2).

RESULTS:

Body weight before ZNS was 78.6 +/- 16.0 kg (range 45-120 kg), BMI 26.5 +/- 5.2 kg/m(2) (range17.6-41.3 kg/m(2)). Within 13 +/- 7.2 months of treatment, mean body weight decreased by -3.7% +/- 9.1%, showing high interindividual variability (-36% to +32%). Weight loss >5% was documented in 35%, weight gain >5% in 14% of patients. Weight loss was more prominent in patients being overweight prior to treatment onset. At the end of follow-up, patients with overweight had decreased by number. Weight changes under ZNS were not correlated to ZNS daily dosage. Following discontinuation of ZNS treatment weight loss proved to be reversible.

CONCLUSION:

Zonisamide reduced weight in 35% of patients, especially in patients with overweight prior to treatment. Weight loss is reversible following discontinuation of treatment with ZNS.

PMID:
19053955
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk